Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

[1]  N. Munshi,et al.  Location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of high-risk NDMM patients. , 2022, Blood.

[2]  E. Shpall,et al.  Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. , 2022, Transplantation and cellular therapy.

[3]  A. Krishnan,et al.  Teclistamab in Relapsed or Refractory Multiple Myeloma. , 2022, The New England journal of medicine.

[4]  K. Rezvani,et al.  Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance , 2021, Leukemia & lymphoma.

[5]  S. Jagannath,et al.  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.

[6]  H. Goldschmidt,et al.  Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.

[7]  Shuku Sato,et al.  Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents , 2020, International Journal of Hematology.

[8]  C. Hofmeister,et al.  Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Krishnan,et al.  Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[11]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[12]  A. El-Ghammaz,et al.  Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis , 2016, Annals of Hematology.

[13]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Miguel,et al.  Defining and treating high-risk multiple myeloma , 2015, Leukemia.

[15]  S. Lonial,et al.  Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients , 2014, Leukemia.

[16]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[17]  I. Bruns,et al.  The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  P. Moreau,et al.  Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Moreau,et al.  Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Grosbois,et al.  Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials , 2007, Leukemia.

[21]  J. Keats,et al.  Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma , 2006, Leukemia & lymphoma.

[22]  D. Reece,et al.  The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant , 2004, British journal of haematology.

[23]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[24]  R. Bataille,et al.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.